Atossa Therapeutics, Inc. ( (ATOS) ) has released its Q4 earnings. Here is a breakdown of the information Atossa Therapeutics, Inc. presented to its investors.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for breast cancer, with its lead product candidate, (Z)-endoxifen, targeting various stages of the disease. In its latest financial report for the year ending December 31, 2024, Atossa announced a cash reserve of $71.1 million and no debt, alongside strategic advancements in its breast cancer treatment programs. Key highlights include the decision to pursue metastatic breast cancer indications for (Z)-endoxifen, promising results from the Phase 2 EVANGELINE trial, and significant reductions in mammographic breast density observed in the Phase 2 KARISMA-Endoxifen study. Financially, Atossa reported a decrease in operating expenses to $27.6 million, driven by reduced research and development costs, and a net loss of $25.5 million for the year. Looking ahead, Atossa remains committed to advancing its clinical programs and exploring regulatory pathways to bring (Z)-endoxifen to market, aiming to address critical unmet needs in breast cancer treatment.